clinical trial · NCT05599789
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
Peking Union Medical College Hospital·phase2·unknown·n = 47
Non Small Cell Lung Cancer MetastaticPembrolizumab in Combination with Plinabulin and Docetaxel
brief summary
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.
started
Feb 1, 2023
primary completion
Jan 21, 2025
completion
Dec 31, 2025
last updated
Feb 18, 2025
official title
A Phase 2 Study of Pembrolizumab in Combination With Plinabulin and Docetaxel in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination With Platinum-doublet Chemotherapy (KeyPemls-004)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol